期刊文献+

凝血酶原复合物制备过程吸附条件的研究 被引量:5

Studies of adsorption conditions in prothrombin complex concehtrates production
下载PDF
导出
摘要 目的探讨凝血酶原复合物制备过程凝血因子Ⅱ、Ⅶ、Ⅸ、Ⅹ的吸附条件,提高活性收率。方法选择DEAE-SephadexA-50凝胶平衡体系中柠檬酸钠、氯化钠、pH 3种可变因素,每因素取3水平,根据L9(33)正交表设计试验,配制平衡液,分别对DEAE-SephadexA-50凝胶进行平衡处理后,按1.67g/L加入等量健康人混合去冷沉淀血浆,4℃搅拌,吸附凝血因子;吸附后凝胶洗涤、洗脱,检测洗脱液中凝血因子Ⅱ、Ⅶ、Ⅸ、Ⅹ活性并进行活性回收率正交试验直观分析,获得较优吸附条件并进行验证。此外,分析吸附平衡体系电导率与4种因子活性收率间关系。结果柠檬酸钠、氯化钠、pH对凝血因子Ⅱ、Ⅶ、Ⅸ、Ⅹ吸附影响不同;在所考察范围内,pH对4种凝血因子吸附影响效应趋势一致,pH越低,吸附效果越佳;柠檬酸钠及氯化钠浓度对4种凝血因子吸附影响效应趋势不一致,柠檬酸钠浓度越高,凝血因子Ⅱ、Ⅶ、Ⅹ吸附越佳,而凝血因子Ⅸ在(0.012~0.02)mol/L水平较佳;氯化钠浓度越低,凝血因子Ⅱ、Ⅶ、Ⅸ吸附越佳,而凝血因子Ⅹ在(0.1~0.14)mol/L水平较佳;平衡体系电导率与4种因子活性收率间不存在线性关系。结论吸附条件中pH及柠檬酸钠浓度对凝血因子Ⅱ、Ⅶ、Ⅸ、Ⅹ吸附效果影响较大。柠檬酸钠(0.02~0.028)mol/L,氯化钠(0.02~0.06)mol/L,pH6.6~6.9条件,4种凝血因子吸附效果相对较佳。电导率对4种因子吸附效果影响不明显。 Objective To study adsorption conditions of coagulation factor Ⅱ、Ⅶ、Ⅸ、Ⅹ in prothromhin complex con- centrates (PCC) production and improve activity recovery of PCC. Methods Orthogonal experiment was designed for the e- quilibration system of DEAE-SephadexA-50 gel. Three variable factors, sodium citrate, sodium chloride and pH, and their re- spective three levels were selected, and then equilibration buffer were prepared based on L9(33 )table. 9 equal parts of the gel were equilibrated respectively by equilibration buffer, and then different equilibrated DEAE-SephadexA-50 gel was mixed with cryoprecipitate supcrnatant in the proportion of 1.67g: 1L for adsorption of coagulation factor Ⅱ、Ⅶ、Ⅸ、Ⅹ, at 4℃. After that, the gel was washed, and then the coagulation factor Ⅱ、Ⅶ、Ⅸ、Ⅹ were eluted. The activity and their recovery of the coagulation factors in the eluate was measured and analyzed on the basis of orthogonal design-direct method. According to analysis results, the better adsorption conditions were obtained, and then were verified. Furthermore, the relationship between conductivity of equilibration system and activity recovery of four kinds coagnlation factors was analyzed. Results Sodium citrate,sodium chloride and pH have diverse impacts on activity recovery of four coagulation factors. The effect of pH on four factors shows same tendency,the lower pH the higher recovery,on the contrary,sodium citrate and sodium chloride have distinct effects on four factors. The higher sodium citrate concentration the higher activity recovery of factors II , g~, X, however the recovery of factor IX is higher when sodium citrate is in (0. 012 - 0. 02)mol/L. The lower sodium chloride concentration the higher recovery of factors Ⅱ、Ⅶ、Ⅸ ,however the recovery offactor X is higher when sodium chloride is in (0. 1 -0. 14) mol/L. It was not line-relation that between conductivity of equilibration system and activity recovery of four kinds coagulation factors. Conclusion The pH and concentration of sodium citrate have greater impact than sodium chloride on the activity recovery of coagulation factors Ⅱ、Ⅶ、Ⅸ、Ⅹ. The recovery of four kinds coagulation factors is relatively higher when sodium citrate (0. 02 - 0. 028 ) tool/L, sodium chloride (0. 02 - 0. 06) mol / L, and pH 6. 6 - 6. 9. The effect of conductivity of equilibration system on activity recovery of four kinds coagulation factors is not obvious.
出处 《中国输血杂志》 CAS CSCD 北大核心 2012年第7期655-660,共6页 Chinese Journal of Blood Transfusion
基金 2009年国家卫生行业科研专项(200902008-2)
关键词 凝血酶原复合物/制备 吸附条件 活性回收率 Prothrombin complex concentrates Production Adsorption conditions Activity recovery
  • 相关文献

参考文献24

  • 1焦丽华,赵辉,余伟,代旭兰,刘文芳.人凝血酶原复合物致血栓形成机制及其评价方法[J].中国输血杂志,2009,22(8):701-703. 被引量:10
  • 2Chandra S,Brummelhuis HGJ. Prothrombin complex concentrates for clinical use. Vox Sang, 1981,41 (4) ;257-273.
  • 3Lusher JM,Shapiro SS,Palascak JE,et al. Efficacy of prothrombin complex concentrates in hemophiliacs with antibodies to FactorVDI. A multicenter therapeutic trial. New Kng J Med, 1980,303 (8 ): 42M25.
  • 4Lorenz R? Kienast J, Otto U, et al. Efficacy and safety of a prothrombin comp lex concentrates with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol, 2003,15 (l):15-20.
  • 5Bohrer H. Prothrombin complex concentrate substitution during liver transplantation.Thromb Res, 1999,95 (Suppl4) S71-74.
  • 6Lankiewicz MW, Hays J, Friedman KD’et al. Urgent reversal of warfarin with prothrombin complex concentrate. Thromb Haemost, 2006,4 (5):967-970.
  • 7Huttner HB,Schellinger PD,Hartmann M,et al. Hemat(xna growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy; comparison of acute treatment strategies using vitamin K,freash 6ozen plasma,and prothrombin complex concentrates. Stroke,2006,37(6) : 1465-1470.
  • 8Godier A. Alternatives to fresh frozen plasma: piotheombin complex concentrate and transfusion guidelines. ISBT, Macao, China, 2008.
  • 9Heystek J, Brummelhuis HGJ, Krijnen HW. Contributions to the opitimal use of human blood. II ? The large scale preparation of prothrombin complex, a comparison between two methods using the anion exchangersDEAE-Cellulose DE52 and DEAE-SephadexA-50. Vox Sang, 1973,25 (2):113-123.
  • 10Tharakan JP, Gee DM, Clark DB. A semi-continuous method for purification of factor IX complex from human plasma. Vox Sang, 1989,57(4) :233-239.

二级参考文献99

  • 1余蓉,赵青蓉,杜俊蓉.不同工艺凝血酶原复合物在兔停滞模型中致血栓性的比较研究[J].中国实验血液学杂志,1996,4(4):416-418. 被引量:2
  • 2黄金明,刁武萍,祝慈芳,吴玮,陈延,韩剑秋.凝血酶原复合物病毒灭活的研究[J].中国生物制品学杂志,1995,8(3):101-104. 被引量:6
  • 3张玉华,凌沛学,籍保平,张天民.糖类在生物活性物质冷冻干燥中的保护作用及其作用机制[J].中国生化药物杂志,2006,27(4):247-249. 被引量:15
  • 4赵彦鼎.人血源凝血因子Ⅸ纯化研究概况[J].中国输血杂志,2006,19(5):412-415. 被引量:5
  • 5Chandra S, Brummelhuis HGJ. Prothrombin complex concentrates for clinical use. Vox Sang,1981,41 (4) :257-273.
  • 6Lorenz R, Kienast J, Otto U, et al. Efficacy and safety of a prothrombin complex concentrates with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol, 2003,15(1) : 15-20.
  • 7Hbert Bohrer. Prothrombin complex concentrate substitution during liver transplantation. Thromb Res, 1999, 95 ( Suppl 4) S71 -74.
  • 8Lusher JM, Shapiro SS, Palascak JE, et al. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to Factor Ⅷ. A multicenter therapeutic trial. New Eng J Med, 1980, 303 (8) :421-425.
  • 9Lankiewicz MW, Hays J, Friedman KD, et al. Urgent reversal of warfarin with prothrombin complex concentrate. Thromb Haemost, 2006,4 (5) :967-970.
  • 10Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, freash frozen plasma, and prothrombin complex concentrates. Stroke, 2006,37 (6) :1465-1470.

共引文献41

同被引文献92

  • 1郑德先,侯充,赵清正,赵玫,王萍,许成素,刘士廉.人蛋白酶抑制因子α_2-巨球蛋白的分离、纯化与鉴定[J].中国医学科学院学报,1995,17(2):148-150. 被引量:1
  • 2邱家山,徐琦,方为茂,钟本和.人凝血酶原复合物分离纯化工艺的研究进展[J].生物技术通报,2006,22(2):17-20. 被引量:4
  • 3Samama CM. Prothrombin complex concentrates :a brief review. EurJ Anaesthesiol,2008,25(10) :784-789.
  • 4Pejaudier L,KicKenin-Martin V,BofEa MC,et al. Appraisal of theprotein composition of prothrombin complex concentrates of differ-ent origins. Vox Sang, 1987,52(1-2) :1-9.
  • 5Pabinger I,Brenner B,Kalina U,et al. Prothrombin complex con-centrate (Beriplexw P/IS ) for emergency anticoagulation reversal :A prospective multinational clinical trial. J Thromb Haemost,2008,6(4) :622-631.
  • 6Leissinger CA, Blatt PM, Hoots WK, et al. Role of prothrombincomplex concentrates in reversing warfarin anticoagulation ; a reviewof the literature. Am J Hematol,2008,83(2) : 137-143.
  • 7Chistolini A, Mazzucconi MG, Tirindelli MC, et al. Disseminatedintravascular coagulation and myocardial infarction in a haemophil-ia B patient during therapy with prothrombin complex concen-trates. Acta Haematol, 1990,83(3) :163-165.
  • 8KaTayalcin G,Goldberg B,Cherrick 1,et al. Acute myocardial in-farction complicating prothrombin complex concentrate therapy inan 8-year-old boy with hemophilia A and factor V JH inhibitor. AmJ Pediatr Hematol Oncol,1993,15(4) :416-419.
  • 9Kbhler M,Hellstem P,Lechler E,et al. Thromboembolic complica-tions associated with the use of prothrombin complex and factor IXconcentrates. Thromb Haemost, 1998,80(3) : 399-402.
  • 10Majeed A,Eelde A,Agen A,et al.Thromboembolic safety and effi-cacy of prothrombin complex concentrates in the emergency reversalof warfarin coagulopathy. Thromb. Res. 2012,129(2) :146-151.

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部